Should Women Get LH Tested?

Should Women Get LH Tested?

Yes, for most women — especially those with irregular cycles, fertility concerns, or symptoms of early menopause. LH (luteinizing hormone) drives ovulation and acts as a real-time readout of the hypothalamic-pituitary-ovarian (HPO) axis. The main caveat: a single random LH value is hard to interpret without knowing cycle day and FSH context. Women on hormonal contraception are the clearest exception — exogenous hormones suppress the axis, making the result uninterpretable.

What Is LH and Why Does It Matter for Women?

Luteinizing hormone is a glycoprotein secreted in pulses by the anterior pituitary in response to gonadotropin-releasing hormone (GnRH) from the hypothalamus. In women, LH has two critical jobs:

1. Trigger ovulation. The mid-cycle LH surge — a sharp 3–10× rise above baseline — causes the dominant follicle to rupture and release an egg, typically 24–36 hours after the surge begins.
2. Support the corpus luteum. After ovulation, LH maintains the corpus luteum so it can produce progesterone during the luteal phase.

When LH is out of range — either chronically elevated, suppressed, or surging at the wrong time — the downstream effects cascade: no ovulation, no progesterone, and disrupted cycle length or fertility. Because LH is tightly coupled to FSH, testing the two together is almost always more informative than either alone. If you're wondering whether FSH testing belongs on your panel too, understanding when women should get FSH tested provides the complementary picture.

The pulsatile nature of LH secretion matters clinically. GnRH neurons in the hypothalamus fire roughly every 60–90 minutes during the follicular phase, and each pulse drives a corresponding LH release from gonadotroph cells in the pituitary. As estrogen rises in the late follicular phase, the feedback switches from negative to positive — a mechanism unique among pituitary hormones — triggering the LH surge that releases the egg. This positive-feedback switch requires estrogen levels to stay above approximately 200 pg/mL for at least 48 hours, which is why women with very thin endometria or estrogen deficiency often fail to generate a proper surge even if the pituitary itself is healthy (Hall, New England Journal of Medicine 1994; PMID: 8264873). Understanding this mechanism clarifies why both the ovary and the hypothalamus must be assessed when an LH result is abnormal.

Normal LH Ranges by Life Stage

LH is not a static marker. Its reference range shifts dramatically depending on where a woman is in her menstrual cycle and her reproductive life stage:

Sources: these reference intervals align with those reported by the Mayo Clinic Laboratories and used in clinical endocrinology practice. Crucially, a postmenopausal-range LH in a woman who still has cycles is a red flag for primary ovarian insufficiency (POI), not a normal finding.

Inter-assay variability is also worth noting: LH immunoassays differ enough between laboratories that a result from one lab should not be directly compared to a result from another without checking which assay and which antibody calibration was used. The WHO 2nd International Standard is the reference preparation, but not all commercial assays are calibrated identically, which can produce differences of 10–20% for the same sample (Beitins & Padmanabhan, Endocrinology and Metabolism Clinics of North America 1991). For serial monitoring — such as tracking LH during ovarian stimulation — using the same laboratory throughout removes this source of variability.

When Should Women Get LH Tested?

Not every woman needs LH on every annual panel, but the following situations make it a high-yield test:

• Irregular or absent periods — oligomenorrhea or amenorrhea almost always warrants LH + FSH to separate central (hypothalamic) from ovarian causes.
• Difficulty conceiving — LH timing guides timed intercourse and IUI protocols; tracking the surge predicts the fertile window.
• Suspected PCOS — polycystic ovary syndrome classically presents with an elevated LH:FSH ratio ≥ 2:1 or ≥ 3:1 (Norman et al., Human Reproduction Update 2002; PMID: 11866247).
• Symptoms of early menopause or POI — hot flashes, night sweats, or irregular cycles before age 45 warrant LH + FSH to assess ovarian reserve.
• Unexplained fatigue or hormonal symptoms — LH helps differentiate adrenal from ovarian dysfunction when combined with cortisol and DHEA-S. Pair this with cortisol testing for women for a fuller picture of HPA-HPO axis health.
• Monitoring fertility treatment — LH is measured repeatedly during ovarian stimulation cycles to time trigger shots.
• Evaluating homocysteine or metabolic cardiovascular risk — chronic anovulation linked to abnormal LH patterns is associated with unfavorable lipid and inflammatory profiles; checking whether women should get homocysteine tested is a useful companion test when PCOS or POI is suspected.

What Abnormal LH Results Usually Mean

High LH

Chronically elevated LH (outside the expected mid-cycle surge) most commonly points to:

• PCOS: LH hypersecretion increases androgen production by theca cells, contributing to the hyperandrogenism and anovulation that define PCOS. A large meta-analysis confirmed that LH:FSH ratio is elevated in roughly 40–60% of PCOS cases, though the ratio alone is no longer required for diagnosis under Rotterdam criteria (Balen et al., Human Reproduction 2016; PMID: 26395770). Crucially, the degree of LH elevation in PCOS correlates with miscarriage risk: women with PCOS who had serum LH > 10 IU/L in the follicular phase showed a miscarriage rate approximately double that of women with lower LH in one prospective cohort (Regan et al., BMJ 1990; PMID: 2108749), underscoring why documenting the LH pattern matters beyond diagnosis.
• Primary ovarian insufficiency: When the ovaries stop responding to gonadotropins, pituitary LH rises in a compensatory attempt to drive follicular development. FSH typically rises first and more steeply, but LH follows.
• Menopause: Postmenopausal women reliably show persistent LH elevations above 10 IU/L, often accompanied by FSH > 40 IU/L.

Low LH

Suppressed LH suggests central (hypothalamic or pituitary) dysfunction:

• Functional hypothalamic amenorrhea (FHA): Seen in athletes, women with very low body weight, or those under severe psychological stress. GnRH pulse frequency drops, pulling LH down with it. A landmark study by Loucks & Thuma showed that energy availability below ~30 kcal/kg fat-free mass/day disrupts LH pulsatility within days (Loucks & Thuma, Journal of Clinical Endocrinology & Metabolism 2003; PMID: 12629127). Importantly, the disruption was dose-dependent: energy availability of 20 kcal/kg/day caused a 50% reduction in LH pulse frequency within five days, demonstrating how rapidly the HPO axis responds to caloric restriction even in otherwise healthy women.
• Hyperprolactinemia: Elevated prolactin suppresses GnRH → LH → ovulation. Testing prolactin alongside LH helps identify pituitary adenomas. Understanding when women should get prolactin tested explains the workup in detail.
• Pituitary damage: Tumors, surgery, radiation, or Sheehan's syndrome can reduce LH secretion.
• Hormonal contraception: OCP, patch, ring, and hormonal IUDs suppress the HPO axis by design — LH values on these methods are pharmacologically lowered and clinically uninterpretable for diagnostic purposes.
• Relative energy deficiency in sport (RED-S): The IOC's consensus framework formally recognizes that low LH pulsatility is the mechanistic link between energy deficiency and bone stress injuries in female athletes (Mountjoy et al., British Journal of Sports Medicine 2014; PMID: 24620037). This makes LH a bone health marker as well as a reproductive one — women with chronically low LH who are not on contraception should also have bone density assessed.

How to Time an LH Test for the Most Useful Result

Timing is everything with LH. Here is the practical protocol:

1. Cycle day 2–5 (early follicular): Best for evaluating baseline LH and calculating the LH:FSH ratio for PCOS workup. Both LH and FSH should be drawn on the same morning blood draw, fasted.
2. Mid-cycle (days 12–14 of a 28-day cycle): Captures the ovulatory surge. Urine LH strips are often used daily in the days before to catch the exact peak. Digital monitors (OPKs) with quantitative LH readout can detect the surge 24–48 hours before ovulation with sensitivity of roughly 97% in research settings.
3. Any day if amenorrheic: When cycles are absent, there is no wrong time to draw LH. A single elevated or suppressed result in this context is already diagnostically useful when interpreted with FSH, prolactin, and estradiol.
4. Repeat testing: A single borderline result should not drive clinical decisions. Repeating LH on two separate cycle days — or across two separate cycles — improves diagnostic confidence, particularly when PCOS or POI is suspected.
5. Morning draw: LH secretion follows a mild diurnal rhythm with higher pulses in the early morning. Standardizing collection to 7–9 AM reduces within-person variability, especially important for serial monitoring.

One practical nuance: home urine LH tests use a different threshold (typically 25–40 IU/L) than serum assays. A positive OPK does not confirm the same thing as a serum LH surge, and women with PCOS may see persistently elevated OPK readings without true ovulation because their tonic LH is already near or above the test threshold. In these women, serum LH — ideally alongside progesterone on day 21 — is necessary to confirm actual ovulation.

How LH Fits Into a Broader Hormonal Panel

LH rarely tells the complete story in isolation. The most clinically informative hormonal workup for a woman presenting with cycle irregularities or fertility concerns typically includes:

For women concerned about cardiovascular risk alongside reproductive hormone changes — particularly those approaching perimenopause — knowing whether women should get cholesterol tested is directly relevant, since estrogen loss driven by LH and FSH dysregulation shifts LDL and HDL profiles unfavorably.

What This Means for Your Formula

LH testing itself is a diagnostic step, not something a supplement changes directly. But the HPO axis that LH reflects is exquisitely sensitive to stress load, cortisol, inflammation, and micronutrient status — all of which are modifiable. Here is where evidence-based supplementation intersects:

Ashwagandha (KSM-66, 600 mg/day): Chronically elevated cortisol is one of the most reliable suppressors of GnRH pulsatility. A randomized, double-blind trial in 60 adults found that KSM-66 at 600 mg/day reduced serum cortisol by 27.9% versus placebo over 60 days (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). By reducing the cortisol load on the hypothalamus, ashwagandha may help restore LH pulsatility in women with stress-driven amenorrhea — though it is not a substitute for addressing the underlying energy or psychological stressor.

Ones Adrenal Support blend: For women whose LH suppression traces back to HPA overdrive, Ones includes a proprietary Adrenal Support system blend designed to buffer the cortisol-GnRH interface. This is particularly relevant for women presenting with the combination of low LH, irregular cycles, and elevated morning cortisol — a pattern Ones' AI can identify when blood work and symptom data are analyzed together.

Vitamin D3 + K2 (MK-7): Vitamin D receptor expression has been documented in granulosa cells, and observational data suggest that vitamin D deficiency is more prevalent among women with PCOS than among reproductively normal controls (Wehr et al., European Journal of Endocrinology 2011; PMID: 21273344). Vitamin D does not normalize LH directly, but its role in ovarian steroidogenesis and insulin sensitivity makes it a meaningful adjunct in women with PCOS-pattern LH elevation. Ones includes D3 + K2 (MK-7) at clinically relevant doses, calibrated to baseline serum 25(OH)D from the user's blood work.

Omega-3 (EPA/DHA): Chronic low-grade inflammation appears to amplify LH-driven androgen production in theca cells in PCOS. EPA and DHA at doses of 2–4 g/day have been shown to reduce circulating androgens and improve menstrual regularity in small PCOS trials (Vargas et al., Gynecological Endocrinology 2011; PMID: 21142777). Ones includes pharmaceutical-grade EPA/DHA dosed to intake gaps identified from dietary and lab data.

Personalized formulas through Ones are built from blood work, not guesswork — which means LH, FSH, cortisol, and vitamin D results can all factor into what goes into your daily capsules.

Key Takeaways

• LH is a real-time readout of ovarian-hypothalamic communication — it reveals whether the HPO axis is functioning, where it's breaking down, and in which direction.
• Cycle timing is non-negotiable — the same LH value means completely different things on day 3 versus day 13 versus in a postmenopausal woman.
• High LH most often points to PCOS or ovarian insufficiency; low LH most often points to hypothalamic suppression from stress, energy deficit, or hyperprolactinemia.
• LH should almost always be drawn alongside FSH, estradiol, and prolactin — no single value tells the full story.
• Women on hormonal contraception get no diagnostic value from LH testing — the HPO axis is pharmacologically suppressed by design.
• Cortisol, vitamin D, and omega-3 status all influence the HPO axis — addressing micronutrient and stress biology is a legitimate and evidence-supported adjunct to whatever clinical intervention an LH abnormality prompts.